The global preterm birth prevention and management market size is estimated to stand at USD 1.70 billion in 2024. As both developed and developing countries embrace therapeutics for preventing and managing preterm birth, the market is expected to exceed a valuation of USD 4.49 billion by 2034, registering an impressive CAGR of 10.2%.
Preterm Birth Prevention and Management Market Overview:
Attributes | Details |
---|---|
Preterm Birth Prevention and Management Market Size (2024) | USD 1.70 billion |
Preterm Birth Prevention and Management Market Forecasted Size (2034) | USD 4.49 billion |
Projected Value CAGR (2024 to 2034) | 10.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Global Concerns Soar as Premature Births Skyrocket! One of the main concerns for governments and medical professionals globally nowadays is the startling rise in the frequency of premature births.
Maternal and Neonatal Health in the Spotlight! The increasing demand is rooted in the recognition of its profound impact on neonatal care in preterm births.
Health Awareness Surge Fuels Market Boom! The market is also booming due to the expanding health awareness among individuals for preterm labor mitigation.
Targeted Therapies Take Center Stage in Preterm Birth Prevention! Increasing emphasis on targeted therapies also escalates the adoption rate of preterm birth prevention and management.
From 2019 to 2023, the global preterm birth prevention and management industry showed promising growth, boasting a 9.0% CAGR. The application of progesterone and corticosteroid medications, among other therapeutic options, was prompted during this period by growing concerns over the mortality rate and long-term impairment associated with obstetric solutions for preterm delivery. These therapeutic methods are likely to continue to gain favor among individuals. The market for preterm birth prevention and management is anticipated to develop considerably as a result through 2034.
Historical CAGR (2019 to 2023) | 9.0% |
---|---|
Forecasted CAGR (2024 to 2034) | 10.2% |
Prominent companies are actively investing in research to create innovative treatments. They are investigating novel combinations of therapies to successfully treat preterm delivery and associated consequences. By treating the fetus as the patient, University of Texas Medical Branch (UTMB) researchers unveiled a novel therapeutic approach in 2021 with the goal of lowering the prevalence of preterm births.
North America stands out as a dominant force in the preterm birth prevention and management industry. The region boasts a robust healthcare infrastructure, advanced medical research facilities, and a proactive approach towards maternal and infant health. There is likely to be significant growth in Asia Pacific. The increasing awareness of maternal and child healthcare, coupled with advancements in medical technology, creates a promising situation for growth of preterm birth prevention and management.
Country | Forecasted CAGR (2024 to 2034) |
---|---|
United States | 8.1% |
India | 12.8% |
China | 11.5% |
Japan | 12.1% |
Indonesia | 13.0% |
Demand for preterm birth prevention and management in the United States is set to rise with an anticipated CAGR of 8.1% through 2034. Key factors influencing the demand include:
The India preterm birth prevention and management market is forecasted to inflate at a CAGR of 12.8% through 2034. The primary factors bolstering the market expansion are:
Sales of preterm birth prevention and management drugs in China are estimated to record a CAGR of 11.5% through 2034. The main factors supporting this occurrence are:
The preterm birth prevention and management market in Japan is likely to exhibit a CAGR of 12.1% through 2034. Reasons supporting this rapid adoption include:
The Indonesia preterm birth prevention and management market is expected to surge at a CAGR of 13.0% through 2034. Top factors supporting the market expansion include:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
As far as the therapy type is concerned, the progesterone segment is likely to dominate the industry in 2024, accounting for a 61.5% market share. Similarly, the parenteral segment is expected to take the lead when considering the route of administration, commanding a 78.8% preterm birth prevention and management market share in the same year. Likewise, when it comes to the distribution channel, the hospital pharmacies segment is anticipated to lead the way, holding an impressive 56.2% market share for the same year.
Segment | Market Share in 2024 |
---|---|
Progesterone Therapy | 61.5% |
Parenteral | 78.8% |
Hospital Pharmacies | 56.2% |
Progesterone therapy is the top choice for preventing preterm births. The following factors support this choice:
The parenteral route dominates the global preterm birth prevention and management market.
Hospital pharmacies hold the maximum revenue share in the distribution channel for preterm birth prevention and management.
Top companies in the global preterm birth prevention and management market are strategically expanding their global footprint through initiatives like mergers, partnerships, product launches, approvals, collaborations, and acquisitions. These diverse approaches reflect their commitment to addressing preterm birth challenges while positioning themselves as industry leaders. Such dynamic strategies underscore their dedication to advancing healthcare solutions and fostering a broader impact on a global scale.
Recent Developments
The preterm birth prevention and management industry is forecasted to be valued at USD 1.70 billion in 2024.
The preterm birth prevention and management market Value is projected to surpass USD 4.49 billion by 2034.
The CAGR of the preterm birth prevention and management industry is estimated to be around 10.2% through 2034.
The United States, India, and Indonesia are key consumers of Preterm Birth Prevention and Management.
In India, the escalating issue of preterm birth is becoming a significant concern, and there is a projected 12.8% CAGR in the efforts toward its prevention and management.
Global trends in preterm birth show a concerning rise, with inadequate healthcare access and lifestyle changes contributing to an increase in premature deliveries
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy Type 5.1. Progesterone Therapy 5.2. Corticosteroid Therapy 5.3. Tocolytics Therapy 5.4. Antihypertensive Therapy 5.5. Magnesium Sulfate Therapy 5.6. Heparin Prophylaxis Therapy 5.7. Low-Dose Aspirin Therapy 5.8. Antibiotics Therapy 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 6.1. Oral 6.2. Parenteral 6.3. Vaginal 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Patient Type 7.1. Prior Spontaneous PTB 7.2. Preeclampsia 7.3. Short Cervix 7.4. Chronic Hypertension 7.5. Insulin-dependent 7.6. Twins 7.7. Antiphospholipid Antibody Syndrome 7.8. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 8.1. Hospital Pharmacies 8.2. Retail Pharmacies 8.3. Drug Stores 8.4. Mail Order Pharmacies 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. South Asia and Pacific 9.6. East Asia 9.7. Middle East and Africa 10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Aquatic Remedies Pvt. Ltd. 19.2. Teva Pharmaceuticals USA, Inc. 19.3. Anglo French Drugs & Industries Limited 19.4. Biophar Lifesciences Pvt. Ltd. 19.5. Jasco Labs (P) Ltd. 19.6. BSA Pharma Inc. 19.7. Pfizer Inc. 19.8. Novartis AG 19.9. Sanofi S.A 19.10. AMAG Pharmaceuticals 19.11. Mylan 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports